stockrowTonix Pharmaceuticals Holding Corp.
TNXP Healthcare Biotechnology
Tonix Pharmaceuticals Holding Corp.’s revenue for fiscal 2025 (year ended December 2025) was $13.1 million, up 29.8% from fiscal 2024.
- Revenue
- +577.9%
- EPS
- +36.8%
- Free cash flow
- −178.8%
Quarter to June 2026, against a year earlier
Follow TNXP
Alert me
Tonix Pharmaceuticals Holding Corp. (TNXP) EV/Sales
As of 6 November 2026, Tonix Pharmaceuticals Holding Corp. (TNXP) trades at a EV/Sales of −3.1×. Over the past ten years it has ranged from −8.5× (March 2025) to 33.9× (August 2025); the current reading is higher than 5% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −5.1× | — |
| FY2024 | −6.6× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.5× | 150.29% |
| Mar 2026 | 0.6× | — |
| Dec 2025 | −5.1× | — |
| Sep 2025 | 3.2× | (78.39%) |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TNXP Tonix Pharmaceuticals Holding Corp. | −3.1× |
| RLYB Rallybio Corporation compare | −0.8× |
| KZIA Novogen Limited compare | n/m |
| TLSA Tiziana Life Sciences Ltd compare | n/m |
| CLLS Cellectis S.A. compare | 0.2× |
| EQ Equillium, Inc. compare | 2.9× |
| GNLX Genelux Corporation compare | 7.0× |
| NRXS Neuraxis, Inc. compare | 12.8× |
| ATRA Atara Biotherapeutics, Inc. compare | 17.7× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)